Protocol Ledger

NCT04838964 · Phase II · COMPLETED

A Study of MRG003 in the Treatment of EGFR-positive Unresectable, Locally Advanced or Metastatic Biliary Tract Cancer

Interventional Phase II clinical trial protocol NCT04838964 sponsored by Lepu Biopharma Co in Oncology and Hematology, reconciled from NIH NLM ClinicalTrials.gov REST API v2.

Start Date: 2021-05-18 Enrollment: 15 participants (ACTUAL) Federal Source: clinicaltrials.gov/study/NCT04838964
Track in Studio / Generate Client Brief ->
Registered Enrollment vs Phase II/III Median (145 pts)15 participants (ACTUAL)
Disclosed U.S. Hospital Campuses vs Median (6 sites)4 sites

Reconciled ClinicalTrials.gov v2 Protocol Specification

Structured Registry Fields for NCT04838964
Protocol FieldVerified Registry Value
NCT IdentifierNCT04838964
Consolidated Lead SponsorLepu Biopharma Co
Therapeutic Condition CohortOncology and Hematology
Clinical Trial PhasePhase II
Overall Recruitment StatusCOMPLETED
Registered Enrollment15 participants (ACTUAL)
Registered Start Date2021-05-18
WhyStopped ClassificationNot Stopped

Named U.S. Hospital Clinical Research Sites

Search related sites and sponsors in the Interactive Directory, explore Oncology and Hematology Benchmarks, or read the Healthcare Price & Patent Cliff Crosswalk.

Need custom healthcare data pipelines, identifier crosswalks, or workflow automation? Talk to Meru AI